Zydus gets rights for next gen I-O platforms from Agenus

4 June 2025

India’s Zydus Lifesciences (BOM:532321) announced that it has entered into a definitive agreement with Agenus (Nasdaq: AGEN) to acquire India and Sri Lanka commercial rights for its investigational botensilimab (BOT) and balstilimab (BAL), combination therapy.

Agenus is a clinical stage immuno-oncology company committed to developing immune therapies that effectively combat cancer. News of the deal pushed its share price up more than 20% to $4.96 by midday trading

Agenus’ lead program comprising botensilimab and balstilimab is a next generation immunotherapy platform designed to strengthen and sustain the immune system’s response against tumour cells. Currently in advanced clinical trials, BOT/BAL have demonstrated significant clinical activity across nine cancer types in more than 1,200 patients, including both late-stage and neoadjuvant settings.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK